This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there’s new treatment for narcolepsy.
Median prevalence of any underlying medical condition 47.2% for residents in all 50 states, DC.
The American College of Rheumatology developed guidance for the management of pediatric patients with multisystem inflammatory syndrome associated with COVID-19.
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the Food and Drug Administration.
Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all evaluated participants.
Sample pooling allows for more people to be tested quickly using fewer testing resources.
Robert Brook, M.D., and May Chu, PhD, discussed importance of face masks during HD Live! interview
Scientists say such ‘human challenge trials’ are of ‘vast importance’ in speeding up the testing of vaccines
HHS asked the CDC on Thursday morning to repost public hospital data on its website.
This week: Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir’s efficacy in severe COVID cases; And several Company’s recall metformin extended release tablets.
